"Pfizer reports lower profit, revenue" is the Marketwatch headline. Unhappy news has become the norm for Pfizer shareholders. Since peaking in 2000 at just under $50/share, the stock has gone nowhere but down for the entire decade – going below $13.00 in 2009 (see Yahoo Finance chart here). You have to go back to 1997 to find the last time Pfizer was valued this lowly. Despite its ownership of several well known, branded drugs – like Viagra and Lipitor – Viagra cannot regain revenue growth or investor interest.
Leadership has done a lot of things the last 10 years to try and improve the business. In 2000, at the valuation peak, the company bought Warner Lambert. In 2002 Pfizer bought Pharmacia (the merged Upjohn/Searle company). In 2005 they spent massively on legal work to protect the remaining patent life on Lipitor. In 2006 they sold the consumer products business to Johnson & Johnson. Across the last 4 years the company has dramatically cut R&D costs for both human and animal products. And earlier this year they agreed to pay a premium to buy Wyeth. But none of this has increased valuation for the last 8 years. To the contrary, value has continued to step down again, and again, and again – losing about 70%.
The problem at Pfizer is management built a Success Formula many years ago, and keeps trying to defend it. They believe in the model of finding, or buying, blockbuster drugs – meaning a product with wide appeal. And selling this only if it has patent protection in order to generate a huge price premium. This made Pfizer huge and profitable long ago. And the company keeps trying to find a way to replay that tune, hoping to achieve the old results.
But the world has shifted. The science of pharmacology has been mined for nearly 100 years. Today, most new drugs have as many problems as benefits. Increasingly, improvement happens only in narrow population niches where genetics align with the chemical additive. Pharmacology is running out of gas. Medical science has shifted to biologics. Instead of looking for a chemical solution, the focus is on nano-tech to isolate product delivery directly to diseased cells. Or engineering to alter genes through cell modification for superior healing performance. These bio-engineering solutions are now offering far better results at far lower cost – while the costs of pharmacology skyrocket amidst diminishing returns.
Pfizer has not shifted. Pfizer management keeps trying to Defend & Extend its old business. Locked-in to the old Success Formula, leadership looks for new drugs, new therapy programs, new solutions that "fit" its approach to the market. But it simply isn't paying off. And everyone from investors to employees to suppliers is at risk. Desperately, leadership is willing to overpay for Wyeth to avoid falling into oblivion when existing drugs come off patent protection in the next few years. But everyone knows this game is nearly over. This may extend the senior leader's jobs, and their pay, it doesn't provide a return to shareholders. Unless leadrship changes the Success Formula Pfizer will never again be as profitable as it once was, or grow as it once did.
Even though it is located in New Jersey, not Michigan, and is full of phramacology Ph.Ds and medical doctors rather than mechanical engineers, Pfizer is more like GM than it would ever admit. It developed a Success Formula, and it is doing everything possible to keep it alive – rather than shift with the market. As GM has shown, no matter how big you are if you don't shift with the market eventually you go bankrupt. Size is no protection from market shifts. Too bad for investors and employees that size is the only thing leadership is trying to use to protect itself.
Don't forget to download the free ebook "The Fall of GM: What Went Wrong and How To Avoid Its Mistakes."
